Literature DB >> 27199064

Statin-Associated Side Effects.

Paul D Thompson1, Gregory Panza2, Amanda Zaleski2, Beth Taylor2.   

Abstract

Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated, but associated with various statin-associated symptoms (SAS), including statin-associated muscle symptoms (SAMS), diabetes mellitus (DM), and central nervous system complaints. These are "statin-associated symptoms" because they are rare in clinical trials, making their causative relationship to statins unclear. SAS are, nevertheless, important because they prompt dose reduction or discontinuation of these life-saving mediations. SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users. Clinically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune myopathy (SINAM), are rare. Antibodies against HMG-CoA reductase apparently provoke SINAM. Good evidence links statins to DM, but evidence linking statins to other SAS is largely anecdotal. Management of SAS requires making the possible diagnosis, altering or discontinuing the statin treatment, and using alternative lipid-lowering therapy.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  interstitial lung disease; myopathy; rhabdomyolysis; skeletal muscle

Mesh:

Substances:

Year:  2016        PMID: 27199064     DOI: 10.1016/j.jacc.2016.02.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  125 in total

1.  Primary Care Physician Perspectives on Barriers to Statin Treatment.

Authors:  Rikki M Tanner; Monika M Safford; Keri L Monda; Benjamin Taylor; Ronan O'Beirne; Melanie Morris; Lisandro D Colantonio; Ricardo Dent; Paul Muntner; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

2.  Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Authors:  Yun-Yan Dai; Hai-Shan Zhang; Xin-Gang Zhang; Qi-Gang Guan; Yuan Gao; Yu-Ze Li; Yue-Lan Zhang; Da-Lin Jia; Ying-Xian Sun; Guo-Xian Qi; Wen Tian
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 3.  Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but….

Authors:  Amanda L Zaleski; Beth A Taylor; Paul D Thompson
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

Review 4.  Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions.

Authors:  Leigh Anne Hylton Gravatt; Rachel W Flurie; Estela Lajthia; Dave L Dixon
Journal:  Curr Atheroscler Rep       Date:  2017-10-09       Impact factor: 5.113

5.  Coronary artery calcium as a predictor of coronary heart disease, cardiovascular disease, and all-cause mortality in Asian-Americans: The Coronary Artery Calcium Consortium.

Authors:  Olusola A Orimoloye; Sandeep Banga; Zeina A Dardari; S M Iftekhar Uddin; Matthew J Budoff; Daniel S Berman; Alan Rozanski; Leslee J Shaw; John A Rumberger; Khurram Nasir; Michael D Miedema; Roger S Blumenthal; Michael J Blaha; Mohammadhassan Mirbolouk
Journal:  Coron Artery Dis       Date:  2019-12       Impact factor: 1.439

6.  Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment.

Authors:  Amanda L Zaleski; Beth A Taylor; Linda S Pescatello; Ellen A Dornelas; Charles Michael White; Paul D Thompson
Journal:  J Cardiovasc Nurs       Date:  2017 Nov/Dec       Impact factor: 2.083

7.  The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis.

Authors:  Zhen Zhou; Loai Albarqouni; Andrea J Curtis; Monique Breslin; Mark Nelson
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

8.  Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.

Authors:  Robert P Giugliano; Stephen D Wiviott; Michael A Blazing; Gaetano M De Ferrari; Jeong-Gun Park; Sabina A Murphy; Jennifer A White; Andrew M Tershakovec; Christopher P Cannon; Eugene Braunwald
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

Review 9.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

10.  Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy.

Authors:  Sijia Yi; Xiaohan Zhang; Hussain Sangji; Yugang Liu; Sean D Allen; Baixue Xiao; Sharan Bobbala; Cameron L Braverman; Lei Cai; Peter I Hecker; Mathew DeBerge; Edward B Thorp; Ryan E Temel; Samuel I Stupp; Evan A Scott
Journal:  Adv Funct Mater       Date:  2019-08-12       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.